If you’re a water resources student in Amarillo, you know the struggle: Texas watersheds often have incomplete streamflow records, making calibration a nightmare. But HEC-HMS v4.14, released in ...

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today ...

Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...

The MarketWatch News Department was not involved in the creation of this content. MONTREAL, April 15, 2026 /CNW/ - To help prepare students from all disciplines for the analytical skills increasingly ...

Behind every hyperscale data centre lies a global free market of energy, copper, and logistics that must be discussed just as much as artificial intelligence. The AI boom sweeping across the United ...

Processing infrastructure at Qatar’s Ras Laffan Industrial City, shown here before hostilities began, includes liquefaction units, pipelines and flare stacks supporting one of the world’s largest LNG ...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting ...